Pedrina Salinas, NP
Nurse Practitioner · Wilmington, NCNPI 1477857746
Payments from drug & device makers
Across 169 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$725
- Amgen$365
- Boehringer Ingelheim$356
- Novo Nordisk$323
- Bayer$234
- Antares Pharma, Inc.$210
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,986100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 30 | $725 |
| Amgen | 27 | $365 |
| Boehringer Ingelheim | 12 | $356 |
| Novo Nordisk | 17 | $323 |
| Bayer | 10 | $234 |
| Antares Pharma, Inc. | 9 | $210 |
| Recordati_rare_diseases_inc. | 8 | $167 |
| AstraZeneca | 2 | $142 |
| Inspire Medical Systems, Inc. | 2 | $137 |
| Corcept Therapeutics | 6 | $137 |
| Teva Pharmaceuticals USA, Inc. | 1 | $124 |
| Mannkind Corporation | 3 | $122 |
| Tandem Diabetes Care, Inc. | 5 | $113 |
| Sanofi-aventis U.S. LLC | 5 | $97 |
| Regeneron Healthcare Solutions, Inc. | 1 | $82 |
| IBSA Pharma Inc. | 4 | $80 |
| Radius Health, Inc. | 4 | $74 |
| Sanofi | 1 | $72 |
| Xeris Pharmaceuticals, Inc. | 3 | $61 |
| Amneal Pharmaceuticals LLC | 3 | $49 |
| BETA Bionics, Inc. | 2 | $46 |
| Insulet Corporation | 1 | $26 |
| Harmony Biosciences LLC | 1 | $25 |
| Abbott | 1 | $22 |
| Chiesi USA, Inc. | 1 | $22 |
| Tolmar, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $19 |
| Pfizer | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Cequr Corporation | 1 | $19 |
| Verity Pharmaceuticals Inc. | 1 | $18 |
| Sequel Med Tech, LLC | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Almatica Pharma LLC | 1 | $16 |
| Acella Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,986 in reported general payments places this provider in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 81 | $118,306 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $50,645 |
| OzempicSemaglutide | 24 | $40,672 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 44 | $28,103 |
| JardianceEmpagliflozin | 14 | $23,426 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $14,665 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $11,878 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $5,191 |
| Novolog FlexpenInsulin Aspart | 11 | $4,004 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $2,866 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 19 | $2,372 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,975 |
| Montelukast Sodium | 56 | $610 |
| Azelastine Hcl | 22 | $591 |
| Levothyroxine Sodium | 18 | $222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $725 | $118,30681 claims |
| Novo NordiskOzempic | $323 | $40,67224 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $142 | $33,29457 claims |
| Boehringer IngelheimJardiance | $356 | $23,42614 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $49 | $22218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.
Other nurse practitioner in Wilmington
- Bridgette WilliamsWilmington$35K
- Kelly GlissonWilmington$30K
- Lauren GardnerWilmington$28K
- Michelle StoughWilmington$24K
- Edith SaffoWilmington$19K
- Rebecca MaphisWilmington$18K
- Breanna BrousseauWilmington$12K
- Anna PaylorWilmington$11K
- Sandrivette JohnsonRaleigh$573K
- Skyler RogersPinehurst$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.